<DOC>
	<DOCNO>NCT01670721</DOCNO>
	<brief_summary>Primary Objective : To evaluate safety aflibercept participant mCRC treat irinotecan/5-Fluorouracil ( 5-FU ) combination ( FOLFIRI ) failure oxaliplatin-based regimen ( participant similar evaluate VELOUR trial [ EFC10262 , NCT00561470 ] ) accord side effect prevention management guideline . Secondary Objective : To document Health-Related Quality Life ( HRQL ) aflibercept participant population .</brief_summary>
	<brief_title>Colorectal Cancer Metastatic</brief_title>
	<detailed_description>Each participant treat disease progression ( DP ) , unacceptable toxicity , death , Investigator 's decision participant 's refusal treatment ( whichever come first ) . Participants followed-up treatment least 30 day last study treatment ( either Aflibercept FOLFIRI ) administration , maximum 6 month .</detailed_description>
	<mesh_term>Colorectal Neoplasms</mesh_term>
	<mesh_term>Neoplasms</mesh_term>
	<mesh_term>Irinotecan</mesh_term>
	<mesh_term>Camptothecin</mesh_term>
	<mesh_term>Fluorouracil</mesh_term>
	<criteria>Inclusion criterion : Histologically cytologically proven adenocarcinoma colon rectum . Metastatic disease . Age â‰¥18 year . Eastern Cooperative Oncology Group ( ECOG ) performance status ( PS ) 01 . One one prior chemotherapeutic regimen metastatic disease . This prior chemotherapy must oxaliplatin contain regimen . Participants must progress follow last administration oxaliplatin base chemotherapy . Participants relapse within 6 month completion oxaliplatin adjuvant chemotherapy also eligible . Participants must affiliate Social Security System . Exclusion criterion : Related Methodology Prior therapy irinotecan ; Absolute neutrophil count ( ANC ) &lt; 1.5 x 109/L ; Platelet count &lt; 100 x 109/L ; Hemoglobin &lt; 9.0 g/dL ; Total bilirubin &gt; 1.5 x upper limit normal ( ULN ) ; Transaminases &gt; 3 x ULN ( unless liver metastasis present , 5 x ULN case ) ; Alkaline phosphatase &gt; 3 x ULN ( unless liver metastasis present , 5 x ULN case ) . Less 4 week elapse prior radiotherapy prior chemotherapy major surgery time inclusion surgical wound fully heal whichever come later ( 48 hour case minor surgical procedure wound full heal observe ) . Treatment investigational drug within 30 day prior inclusion . AEs ( exception alopecia , peripheral sensory neuropathy list specific exclusion criterion ) prior anti cancer therapy grade &gt; 1 National Cancer Institute Common Terminology Criteria Adverse Events [ NCI CTCAE ] v.4.0 time inclusion . History brain metastasis , uncontrolled spinal cord compression , carcinomatous meningitis new evidence brain leptomeningeal disease . Other prior malignancy . Basal cell squamous cell skin cancer , carcinoma situ cervix cancer participant disease free &gt; 5 year allow . Any follow within 6 month prior inclusion : myocardial infarction , severe/unstable angina pectoris , coronary/peripheral artery bypass graft , New York Heart Association ( NYHA ) class III IV congestive heart failure , stroke transient ischemic attack . Any follow within 3 month prior inclusion : Grade 34 gastrointestinal bleeding/hemorrhage , treatment resistant peptic ulcer disease , erosive oesophagitis gastritis , infectious inflammatory bowel disease , diverticulitis , pulmonary embolism uncontrolled thromboembolic event . Occurrence deep vein thrombosis within 4 week , prior inclusion . Known acquired immunodeficiency syndrome ( AIDS ) relate illness know human deficiency virus ( HIV ) disease require antiretroviral treatment . Any severe acute chronic medical condition , could impair ability participant participate study interfere interpretation study result . Pregnant breastfeed woman . Positive pregnancy test woman reproductive potential . Participants reproductive potential ( female male ) agree use method contraception study treatment period least 6 month follow completion study treatment . The definition effective method leave investigator 's judgment . Related Aflibercept : Urine proteincreatinine ratio ( UPCR ) &gt; 1 morning spot urinalysis proteinuria &gt; 500 mg/24h . Serum creatinine &gt; 1.5 x ULN . If creatinine 1.01.5 x ULN , creatinine clearance , calculate accord CockroftGault formula , &lt; 60 ml/min exclude participant . Uncontrolled hypertension ( blood pressure &gt; 140/90 mmHg systolic blood pressure &gt; 160 mmHg diastolic blood pressure &lt; 90 mmHg , least 2 repeated determination separate day , upon clinical judgement within 3 month prior study inclusion . Participants anticoagulant therapy unstable dose warfarin and/or outoftherapeutic range international normalize ratio ( INR ) ( &gt; 3 ) within 4 week prior inclusion . Evidence clinically significant bleed diathesis underlie coagulopathy ( e.g . INR &gt; 1.5 without vitamine K antagonist therapy ) , nonhealing wound . Related FOLFIRI Known dihydropyrimidine dehydrogenase deficiency . Predisposing colonic small bowel disorder symptom uncontrolled indicated baseline &gt; 3 loose stool daily . Prior history chronic enteropathy , inflammatory enteropathy , chronic diarrhea , unresolved bowel obstruction/subobstruction , hemicolectomy , extensive small intestine resection chronic diarrhea . History anaphylaxis know intolerance atropine sulphate loperamide appropriate antiemetic administer conjunction FOLFIRI . Treatment concomitant anticonvulsivant agent cytochrome P450 3A4 ( CYP3A4 ) inducer ( phenytoin , phenobarbital , carbamazepine ) , unless discontinue &gt; 7 day . Participants know Gilbert 's syndrome . The information intend contain consideration relevant participant 's potential participation clinical trial .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>October 2016</verification_date>
</DOC>